Genmab — Februar 2025
-
as i know there are some Dutch readers here... Gunstige uitkomsten profylaxe met Mim8 bij hemofilie A-patiënten https://www.mednet.nl/congres-nieuws/gunstige-uitkomsten-profylaxe-met-mim8-bij-hemofilie-a-patienten/
-
Det mest sandsynlige er vel trods alt, at der ikke kommer et bud. Base rate (andelen af bio/pharma-selskaber i Genmabs størrelsesorden, der overtages i et gennemsnitligt år) er jo meget lav. Så kan der være nogle specifikke forhold, der skubber sandsynligheden lidt op for Genmab relativt til base rate, men sandsynligheden er stadig væsentligt under 50%.
-
Minhua Chu
@chuminhua432
1/ $JNJ received approval in #China for two novel bispecific antibodies: Talvey (talquetamab) as a monotherapy for 4L R/R MM, who have previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody; Rybrevant (amivantamab) 1L EGFR ex20ins NSCLC https://x.com/chuminhua432/status/1889219300973801765 -
Teknisk problem ifølge deres Twitter/X-konto.
-
-
Så må man jo håbe, at man ikke opdager, at en finne har solgt hele ens beholdning, men til gengæld sørget for, at man er blevet majoritetsaktionær i et svensk microcap med negativ egenkapital, når man engang kan logge på igen.
-
Nordnet ramt af sikkerhedslæk - aktien falder https://proinvestor.com/investornyt/1276704/nordnet-ramt-af-sikkerhedslaek-aktien-falder
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
